Neurotrope to Showcase Bryostatin as a Potential Treatment for Alzheimer’s Disease at the 2015 Alzheimer’s Association International Conference
Newark, NJ, July 20, 2015 – Neurotrope, Inc. (OTCQB: NTRP) today announced that Neurotrope Bioscience, Inc., its wholly-owned operating subsidiary, (the “Company”) will be showcasing bryostatin as a potential treatment for Alzheimer’s Disease at the Alzheimer’s Association International Conference(R)(AAIC) being held July 18-23, 2015, in Washington, DC.
Neurotrope Bioscience has an exclusive license to develop and commercialize bryostatin for cognitive disorders. Bryostatin is a potent modulator of an enzyme called protein kinase C epsilon (PKCε), which has been studied extensively by the Blanchette Rockefeller Neurosciences Institute (BRNI) as a possible treatment of cognitive disorders. Based upon a number of BRNI pre-clinical and autopsy-validated human tissue studies, PKCε deficits have been implicated as a potential cause of Alzheimer’s disease. The Company is approaching the treatment of Alzheimer’s disease through the activation of PKCε. In animal models of Alzheimer’s disease, activation of PKCε has been shown to improve learning and memory, increase brain neurotropic factors, and induce synaptogenesis. The Company expects to initiate a Phase 2b trial of bryostatin-1 in approximately 150 patients with moderately severe to severe Alzheimer’s disease later this year.
About the Alzheimer’s Association International Conference(R)(AAIC)
The Alzheimer’s Association International Conference(R)(AAIC) is the world’s largest forum for the dementia research community. International investigators, clinicians and care providers gather annually to share the latest study results, theories and discoveries to bring the world closer to breakthroughs in dementia science.
About Alzheimer’s Disease
According to the Alzheimer’s Association, it is estimated that over 5.4 million people in the United States suffer from Alzheimer’s disease. Over 500,000 patients are diagnosed annually, with nearly one-in-eight older Americans affected by the disease. Alzheimer’s disease is the third leading cause of death in the United States. There is no cure or effective treatment for Alzheimer’s disease. Worldwide, about 35.6 million individuals have the disease and, according to the World Health Organization, the number will double every 20 years to 115.4 million people with Alzheimer’s by 2050.
Neurotrope BioScience, Inc., a wholly owned subsidiary of Neurotrope, Inc., is at the forefront of biotechnology companies having a focus on developing a novel therapy for the treatment of moderately severe to severe Alzheimer’s disease. The scientific basis of our treatment is activation of Protein Kinase C isozymes ε and α by bryostatin, a natural product, which can result in enhancement of existing synapses, reduces toxic amyloid generation, promotes synaptogenesis, and enhances memory and learning, thus having the potential to improve cognitive function in Alzheimer’s disease. The Company plans to initiate our Phase 2b in 150 moderately severe to severe Alzheimer’s patients in Q4 2015.
Neurotrope is also conducting preclinical studies of bryostatin as a treatment for Fragile X Syndrome and Niemann-Pick Type C, two rare genetic diseases for which only symptomatic treatments are currently available. We have recently been granted Orphan Drug Designation for bryostatin as treatment of Fragile X Syndrome.
NTRP has exclusive licensed technology from the Blanchette Rockefeller Neurosciences Institute for Alzheimer’s disease and Fragile X Syndrome, has a world-wide, exclusive license with the Icahn School of Medicine at Mt. Sinai for Niemann-Pick Type C and is partnered with Stanford University to find the next generation bryostatin – called bryologs.
About The Blanchette Rockefeller Neurosciences Institute
Located in Morgantown, WV, BRNI, at West Virginia University, is a unique, independent, non-profit institute dedicated to the study of memory and finding solutions to memory disorders. BRNI was founded in 1999 in memory of Blanchette Ferry Hooker Rockefeller, an Alzheimer’s patient and mother of U. S. Senator John D. Rockefeller IV. BRNI is operated in alliance with West Virginia University as well as in collaboration with other academic institutions.
Any statements contained in this press release, or made during the Company’s presentation at this conference that do not describe historical facts may constitute forward-looking statements. These forward-looking statements include statements regarding the proposed study and goals, the expectation for timing of results, and continued development of use of bryostatin for Alzheimer’s disease. Such forward-looking statements are subject to a number of risks and uncertainties and other influences, many of which the Company has no control over. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of these risks and uncertainties. Factors that may influence or cause actual results to differ materially from expected or desired results may include, without limitation, the Company’s inability to obtain adequate financing, the significant length of time associated with drug development and related insufficient cash flows and resulting illiquidity, the Company’s patent portfolio, the Company’s inability to expand the Company’s business, significant government regulation of pharmaceuticals and the healthcare industry, lack of product diversification, availability of the Company’s raw materials, existing or increased competition, stock volatility and illiquidity, and the Company’s failure to implement the Company’s business plans or strategies. These and other factors are identified and described in more detail in the Company’s filings with the SEC, including the Company’s Annual Report on Form 10-Q for the fiscal quarter ended March 31, 2015. The Company does not undertake to update these forward-looking statements.
Please visit www.neurotropebioscience.com for further information.
For additional information, please contact:
Chief Financial Officer